(This article was originally sent to Jim Cramer and members of CNBC Investing Club. Get the latest updates directly to your email subscribe here.)

Once you get this email, 100 shares will be sold to you AbbVie (ABBV)Around $135.78 The Charitable Trust will now own 1,000 AbbVie shares following the trade. This trimming will reduce ABBV’s portfolio weight from 3.53% down to 3.22%.

On Wednesday, we will make a slight trim in the stock which has been at its 52 week high every day. We are removing shares from stocks that push to new heights during the market recovery. This is to replenish cash we have actively invested at lower prices.

AbbVie, which has seen a tremendous performance over the past month thanks to several reasons, gained more than 16% in December. Let’s look at each one.

One of the most controversial topics at AbbVie’s company level was whether or not the FDA would clamp down on JAK inhibitor classes due to safety concerns. Rinvoq, however, has been proven safe and effective in every study. Rinvoq, one of AbbVie’s most valuable growth drugs, would be affected if the FDA imposes strict labeling. Rinvoq will replace large amounts of sales lost by Humira’s patent protection in the United States.

After Rinvoq was approved by the FDA for treatment of adult psoriatic arthritis, it seems that the bear thesis against AbbVie has taken a significant step back. According to the FDA, Rinvoq may soon be approved by the JAK Class at large. This means that AbbVie’s floor of 2023 earnings per share is likely higher than the bears believe.

Stock investors are likely to have bought AbbVie as a result of the large and safe dividend, low price-to earnings valuation, and other concerns about an economic slowdown.

On a sector-by-sector basis, health insurance has been in favour lately as they can increase earnings even during economic downturns. The Blocking of Build Back Better was seen as an unfair win for drug stocks, which were able to be negotiated directly by the government with certain pharmaceutical companies about the prices of drugs.

As you can see there are many reasons AbbVie is on the rise lately. Even with today’s trimming, we believe the stock will go higher in 2022. That is why the Charitable Trust position remains relatively large.

Our belief is that the stock’s low multiple price-to-earnings has discounted Humira’s loss of exclusivity. The Rinvoq, Skyrizi and Medical Aesthetics launches were executed well by management. We expect these themes to continue next year. The 4.15% dividend, which is a nice payment while we wait for Humira to unfold, is also an attractive one.

Our oldest lot, which was born in October 2019, has experienced a phenomenal gain of 82%. That is why we are trying to secure it today.

My Charitable Trust now has an official home at the CNBC Investing Club. This is where I share my market intelligence and every move that we have made for our portfolio. Action Alerts Plus is not affiliated in any way with the Charitable Trust or my writings.

 Subscribers to CNBC Investing Club will get a trade alert prior to Jim making a trade. Jim will wait 45 minutes to send a trade alert, before buying or selling stock from his charitable trust portfolio. Jim can wait up to 72 hours before trading if Jim discussed the stock on CNBC TV. See here for the investing disclaimer.

 (Jim Cramer Charitable Trust was long ABBV.